[Featured Stock] Korea BNC Surges After US FDA Phase 2 Confirms Antroquinonol Effectiveness Against COVID-19 Variants

[Asia Economy Reporter Minwoo Lee] The stock price of Korea BNC is on the rise. The news that the COVID-19 treatment candidate substance undergoing Phase 2 clinical trials by the U.S. Food and Drug Administration (FDA) has confirmed therapeutic effects against variant viruses appears to have acted as a positive factor.

At 10:33 a.m. on the 15th, Korea BNC's stock price recorded 21,500 KRW, up 11.11% compared to the previous day. The news confirming the effectiveness of the COVID-19 treatment candidate substance 'Antroquinonol,' which is undergoing Phase 2 clinical trials by the U.S. FDA, seems to have had a positive impact.

Korea BNC announced on the 15th that it confirmed the excellent antiviral, anti-inflammatory, and anti-pulmonary fibrosis effects of Antroquinonol through the PCT patent application data of Taiwan's Golden Biotech and expects it to be effective against variant viruses.

The company stated that, based on the PCT patent application contents received through Golden Biotech, it concluded that the Antroquinonol compound has excellent antiviral, anti-inflammatory, and anti-pulmonary fibrosis effects related to the COVID-19 virus.

It also emphasized that Antroquinonol shows excellent antiviral effects as well as inhibitory effects on virus-induced inflammation and pulmonary fibrosis. It explained that if the NSP7 protein, which Antroquinonol acts on, maintains complementarity with variant viruses, Antroquinonol will have a high antiviral inhibitory effect against variant viruses as well.

Earlier, Korea BNC received approval from the U.S. FDA to conduct clinical trials targeting mild to moderate patients hospitalized with COVID-19. According to the clinical trial information site 'ClinicalTrials' operated by the U.S. National Institutes of Health (NIH), the clinical trial is scheduled to conclude in December.

This content was produced with the assistance of AI translation services.